MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
45.03
+1.08
+2.46%
After Hours: 44.16 -0.87 -1.93% 16:31 02/06 EST
OPEN
44.29
PREV CLOSE
43.95
HIGH
46.18
LOW
42.79
VOLUME
663.46K
TURNOVER
--
52 WEEK HIGH
49.25
52 WEEK LOW
6.71
MARKET CAP
2.17B
P/E (TTM)
-16.7803
1D
5D
1M
3M
1Y
5Y
1D
Maze Therapeutics Announces Sales Agreement Prospectus Supplement Covering Offering Of Up To $200M Of Common Stock
Benzinga · 2d ago
Maze Therapeutics Files For Mixed Shelf; Size Not Disclosed
Benzinga · 2d ago
Maze Therapeutics files automatic mixed securities shelf
TipRanks · 2d ago
Maze Therapeutics Secures New $200 Million Loan Facility
TipRanks · 2d ago
MAZE THERAPEUTICS : SALES AGREEMENT PROSPECTUS SUPPLEMENT COVERING OFFERING OF UP TO $200 MLN OF COMMON STOCK
Reuters · 2d ago
MAZE THERAPEUTICS INC FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING
Reuters · 2d ago
MAZE THERAPEUTICS INC - HERCULES TERM LOAN FACILITY MATURES FEBRUARY 1, 2031 - SEC FILING
Reuters · 2d ago
Maze Therapeutics Secures Up to $200 Million Term Loan Facility from Hercules Capital
Reuters · 2d ago
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.